Evidence map›Paper›PMID 38746950›Full record

ArticleOpen forum infectious diseases2024

National HIV and HCV Screening Rates for Hospitalized People who Use Drugs Are Suboptimal and Heterogeneous Across 11 US Hospitals.

Leo Knudsen Westgard, Taisuke Sato, William S Bradford, Ellen F Eaton, Finlay Pilcher, Andrew J Hale, Devika Singh, Marlene Martin, Ayesha A Appa, Jaimie P Meyer and 15 more

Registry-linked trialAbstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07560046 (Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07560046 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations

TypeinterventionalSponsorDuke UniversityRan2026 to 2030Enrolled1,280ConditionsHIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)ArmsCepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2, Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Syringe Services Participants' Preferences for Wound Care, HIV/Hepatitis C Virus Screening, and Opioid Use Disorder Treatment: A Discrete Choice Experiment.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Leo Knudsen WestgardTufts Medical Center, Boston, Massachusetts, USA.
Taisuke SatoTufts Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6830-2812
William S BradfordUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Ellen F EatonUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Finlay PilcherLarner College of Medicine, University of Vermont, Burlington, Vermont, USA.
Andrew J HaleLarner College of Medicine, University of Vermont, Burlington, Vermont, USA.
Devika SinghLarner College of Medicine, University of Vermont, Burlington, Vermont, USA.
Marlene MartinZuckerberg San Francisco General Hospital, San Francisco, California, USA.
Ayesha A AppaUniversity of California, San Francisco, California, USA.
Jaimie P MeyerYale School of Medicine, New Haven, Connecticut, USA.
Melissa B WeimerYale School of Medicine, New Haven, Connecticut, USA.
Lydia A BarakatYale School of Medicine, New Haven, Connecticut, USA.
Uriel R FelsenMontefiore Medical Center, Bronx, New York, USA.
Matthew J AkiyamaMontefiore Medical Center, Bronx, New York, USA.
Jessica P RidgwayUniversity of Chicago, Chicago, Illinois, USA.
Emily D GrussingTufts Medical Center, Boston, Massachusetts, USA.
Kinna ThakararTufts University School of Medicine, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-4689-0240
Amy WhiteMaine Medical Center Research Institute, Portland, Maine, USA.
John MutelayiMaine Medical Center Research Institute, Portland, Maine, USA.
Martin KrsakUniversity of Colorado School of Medicine, Denver, Colorado, USA.ORCID https://orcid.org/0000-0002-1746-7462
Brian T MontagueUniversity of Colorado School of Medicine, Denver, Colorado, USA.
Ank NijhawanUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA.
Harini BalakrishnanUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA.
Laura R MarksWashington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Alysse G WurcelTufts Medical Center, Boston, Massachusetts, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)UM1TR004398 · NCATS · TUFTS UNIVERSITY BOSTON · PI Harry P. Selker · 2023 to 2026
$44.5M
Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HARRIS GOLDSTEIN · 2017 to 2026
$28.3M
AHRQ HHS T32 HS013852NCATS NIH HHS UL1 TR001863NCATS NIH HHS UM1 TR004398NIAID NIH HHS P30 AI124414
6 · The paper itself

Abstract

Background: To end the HIV and hepatitis C virus (HCV) epidemics, people who use drugs (PWUD) need more opportunities for testing. While inpatient hospitalizations are an essential opportunity to test people who use drugs (PWUD) for HIV and HCV, there is limited research on rates of inpatient testing for HIV and HCV among PWUD. Methods: Eleven hospital sites were included in the study. Each site created a cohort of inpatient encounters associated with injection drug use. From these cohorts, we collected data on HCV and HIV testing rates and HIV testing consent policies from 65 276 PWUD hospitalizations. Results: Hospitals had average screening rates of 40% for HIV and 32% for HCV, with widespread heterogeneity in screening rates across facilities. State consent laws and opt-out testing policies were not associated with statistically significant differences in HIV screening rates. On average, hospitals that reflexed HCV viral load testing on HCV antibody testing did not have statistically significant differences in HCV viral load testing rates. We found suboptimal testing rates during inpatient encounters for PWUD. As treatment (HIV) and cure (HCV) are necessary to end these epidemics, we need to prioritize understanding and overcoming barriers to testing.

Indexed as

hepatitis C testingHIV testinghospitalizationinjection drug usepeople who inject drugs

Identifiers

PMID38746950
PMCPMC11093397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.